

LEPTOSPIROSIS IS HARD TO DETECT. NOW HELPING PREVENT IT CAN BE EASY.


Equine leptospirosis is a bacterial disease caused by spirochetes belonging to the genus *Leptospira*. Because the clinical signs of infection are often nonspecific, disease in horses may be underdiagnosed.

HORSES ACROSS THE COUNTRY MAY BE AT RISK.

Serologic studies show that exposure to *Leptospira* may be more prevalent than previously understood.^{1,2} In a 2014 study of 5,261 healthy horses, 75% of the horses tested positive for at least one leptospiral serovar.¹

REGIONAL SEROPREVALENCE

- Northeast — 69.1%
- South — 77.0%
- Midwest — 76.2%
- Pacific Northwest — 69.0%
- Southwest — 77.5%



HELP PROTECT YOUR PATIENTS WITH LEPTO EQ INNOVATOR®

Developed specifically for horses, LEPTO EQ INNOVATOR is the first and only equine vaccine to help prevent leptospirosis caused by *L. pomona* and can help reduce the spread of leptospirosis. The vaccine targets *Leptospira interrogans* serovar Pomona, which is most frequently associated with disease in horses.³

LEPTO EQ INNOVATOR helps prevent leptospiremia caused by *L. pomona*, which could, but has not been demonstrated to, help reduce the potential risk of equine recurrent uveitis, abortion or acute renal failure caused by *L. pomona*.*


DEMONSTRATED TO BE SAFE AND EFFECTIVE

In safety and efficacy trials, LEPTO EQ INNOVATOR was shown to provide a safe immune response. An efficacy study demonstrated that horses vaccinated with LEPTO EQ INNOVATOR and challenged with *L. pomona* showed 0% urinary shedding.⁴

- In field safety studies with administration of 2,272 vaccine doses, 99.9% of the horses were reaction-free.⁵⁻⁷
- No significant adverse events were attributed to vaccine administration.⁵⁻⁷
- Field safety studies examined the vaccine when used in 457 pregnant mares across the first, second and third trimesters and showed no systemic or local reactions were attributed to vaccine administration.^{6,7}

USDA-LICENSED FOR USE IN ALL TRIMESTERS OF PREGNANCY

LEPTO EQ INNOVATOR® IS PART OF A BROAD RANGE OF TRUSTED VACCINES FROM ZOETIS.



TO TAKE THE LEPTOSPIROSIS RISK ASSESSMENT AND LEARN MORE ABOUT LEPTO EQ INNOVATOR®, VISIT **LEPTOEQINNOVATOR.COM** OR CONTACT YOUR ZOETIS REPRESENTATIVE.

*Currently, there are no vaccines available with USDA-licensed label claims against equine abortions, uveitis or acute renal failure due to *L. pomona*.

†This product license is conditional. Efficacy and potency test studies are in progress. Please consult your veterinarian.

References:

- ¹ Data on file, Study Report No. Restricted Grant-FTLEPT013 (v1.0) TI-01366, Zoetis LLC.
- ² Carter CN, Cohen N, Steinman MN, Smith JL, Erol E, Brown S. Seroepidemiology of equine leptospirosis utilizing diagnostic laboratory specimens from 29 states (US) and one Canadian province, in *Proceedings*. 55th Annu AAVLD Meet 2012;51.
- ³ Divers TJ, Chang Y-F. Leptospirosis. In: Robinson NE, Sprayberry KA, eds. *Current Therapy in Equine Medicine*. Vol 6. 6th ed. St. Louis, MO: Saunders Elsevier;2009:145-147.
- ⁴ Data on file, Study Report No. B850R-US-12-011, Zoetis LLC.
- ⁵ Data on file, Study Report No. B951R-US-13-043, Zoetis LLC.
- ⁶ Data on file, Study Report No. B951R-US-13-046, Zoetis LLC.
- ⁷ Data on file, Study Report No. B951R-US-15-092, Zoetis LLC.